Companies

Search, filter and compare every US company we cover.

Search companies

Sector

Industry

Size

Today

Profitable Growing

Add filter

Clear all

Net debt

Min billion $ Max billion $

77 companies match

Sort by

Market cap

Highest first

Company	Industry	Market cap	Price	Day change	Revenue	Revenue growth	Operating margin	P/E	5-yr growth	Gross margin	Net margin	Free cash flow	FCF margin	Return on capital	Return on equity	Net debt	Net debt / EBITDA	Dividends + buybacks	Share count change	F-score	Insider buys (90d)	Insider sales (90d)
BeOne Medicines Ltd.ONC	Pharmaceutical Preparations	$551.0B	$366.06	1.3%	$5.3B	40.2%	8.4%	—	76.8%	87.5%	5.4%	$942M	17.6%	46.7%	7.5%	−$3.7B	−6.3x	—	7.8%	8	$0.0M	$124M
Zai Lab LtdZLAB	Pharmaceutical Preparations	$26.3B	$23.58	3.1%	$460M	15.3%	−49.9%	—	56.5%	58.6%	−38.1%	−$159M	−34.5%	−78.6%	−22.6%	−$485M	—	—	10.7%	3	$0.0M	$0.2M
INSMED IncINSM	Pharmaceutical Preparations	$20.6B	$94.96	1.7%	$606M	66.7%	−205.6%	—	29.8%	79.7%	−210.5%	−$968M	−159.6%	—	−249.3%	−$859M	—	—	21.3%	4	$0.0M	$39.2M
Madrigal Pharmaceuticals, Inc.MDGL	Pharmaceutical Preparations	$12.8B	$440.33	0.6%	$958M	432.1%	−31.3%	—	—	—	−30.1%	−$190M	−19.8%	—	−42.5%	−$644M	—	—	5.6%	3	$0.0M	$6.6M
Axsome Therapeutics, Inc.AXSM	Pharmaceutical Preparations	$7.4B	$142.20	1.3%	$638M	65.5%	−26.1%	—	—	—	−28.7%	−$93.9M	−14.7%	—	−252.1%	−$128M	—	—	3.8%	4	$0.0M	$12.6M
Ionis Pharmaceuticals IncIONS	Pharmaceutical Preparations	$7.3B	$43.96	1.2%	$944M	33.8%	−40.4%	—	5.3%	98.3%	−40.4%	−$320M	−33.9%	—	−70.8%	−$865M	—	—	7.0%	3	$1.1M	$0.1M
Rhythm Pharmaceuticals, Inc.RYTM	Pharmaceutical Preparations	$6.3B	$92.18	3.0%	$190M	45.8%	−101.2%	—	—	89.7%	−103.6%	−$117M	−61.5%	—	−244.5%	−$281M	—	—	6.5%	6	$0.0M	$28.8M
Ptc Therapeutics, Inc.PTCT	Pharmaceutical Preparations	$5.7B	$62.09	1.7%	$1.7B	114.5%	50.1%	—	35.4%	—	39.4%	$702M	40.6%	—	—	−$1.7B	−1.8x	—	14.9%	6	$0.0M	$8.5M
Cogent Biosciences, Inc.COGT	Pharmaceutical Preparations	$5.5B	$32.01	3.6%	—	—	—	—	—	—	—	−$266M	—	—	−73.7%	−$678M	—	—	24.1%	3	$0.0M	$1.7M
Arcutis Biotherapeutics, Inc.ARQT	Pharmaceutical Preparations	$4.3B	$31.68	0.4%	$376M	91.3%	−3.3%	144.0x	—	90.2%	−4.3%	−$6.3M	−1.7%	−12.5%	−9.3%	−$112M	—	—	5.2%	4	$0.0M	$2.3M
Disc Medicine, Inc.IRON	Pharmaceutical Preparations	$3.1B	$79.90	2.9%	—	—	—	—	—	—	—	−$181M	—	—	−35.9%	−$762M	—	—	27.9%	3	$0.0M	$13.6M
Dyne Therapeutics, Inc.DYN	Pharmaceutical Preparations	$2.8B	$16.94	7.8%	—	—	—	—	—	—	—	−$405M	—	−3,526.6%	−55.7%	−$962M	—	—	36.4%	3	$0.0M	$65.7M
Precigen, Inc.PGEN	Pharmaceutical Preparations	$2.5B	$6.15	1.8%	$9.7M	146.7%	−1,141.1%	—	−21.3%	—	−2,588.2%	−$89.8M	−927.6%	−538.0%	−843.6%	−$4.7M	—	—	16.9%	2	$0.0M	$3.4M
Arcus Biosciences, Inc.RCUS	Pharmaceutical Preparations	$2.3B	$18.14	2.1%	$247M	−4.3%	−156.3%	—	25.9%	—	−142.9%	−$484M	−196.0%	—	−63.3%	−$882M	—	—	19.2%	0	$0.0M	$0.1M
Vera Therapeutics, Inc.VERA	Pharmaceutical Preparations	$2.2B	$29.99	6.0%	—	—	—	—	—	—	—	−$242M	—	—	−50.7%	−$640M	—	$0.0M	16.1%	1	$0.0M	$1.3M
Sarepta Therapeutics, Inc.SRPT	Pharmaceutical Preparations	$2.0B	$18.89	5.1%	$2.2B	15.6%	−31.8%	—	32.4%	98.8%	−32.5%	−$307M	−14.0%	−53.7%	−53.5%	−$111M	—	$25.0M	−7.2%	4	$0.0M	$0.0M
Zenas BioPharma, Inc.ZBIO	Pharmaceutical Preparations	$1.7B	$27.30	0.2%	$10.0M	100.0%	−3,830.6%	—	—	—	−3,777.4%	−$172M	−1,723.5%	—	−136.2%	−$265M	—	—	238.9%	2	$0.0M	$0.0M
COMPASS Pathways plcCMPS	Pharmaceutical Preparations	$1.6B	$11.81	6.9%	—	—	—	—	—	—	—	—	—	—	−565.3%	−$100M	—	—	38.6%	1	$0.0M	$0.0M
Omeros CorpOMER	Pharmaceutical Preparations	$1.6B	$17.49	7.4%	—	—	—	10.1x	—	—	—	−$116M	—	—	—	−$82.7M	—	$0.0M	—	—	$0.0M	$2.2M
uniQure N.V.QURE	Pharmaceutical Preparations	$1.5B	$24.28	12.1%	$16.1M	−40.6%	−1,151.4%	—	−15.6%	89.5%	−1,236.0%	−$178M	−1,108.2%	−76.8%	−207.1%	−$8.3M	—	—	18.2%	4	$0.0M	$0.0M
Savara IncSVRA	Pharmaceutical Preparations	$1.2B	$4.86	7.5%	—	—	—	—	—	—	—	−$101M	—	—	−63.5%	−$206M	—	—	12.2%	2	$0.0M	$0.0M
GH Research PLCGHRS	Pharmaceutical Preparations	$1.2B	$20.02	4.4%	—	—	—	—	—	—	—	−$43.7M	—	−143.4%	−21.0%	−$246M	—	—	17.3%	3	$0.0M	$0.0M
Opko Health, Inc.OPK	Pharmaceutical Preparations	$1.2B	$1.61	1.2%	$607M	−14.9%	−19.3%	—	−15.8%	33.9%	−37.2%	−$191M	−31.4%	−7.4%	−17.1%	−$15.4M	—	$47.0M	8.2%	4	$0.0M	$0.0M
Alto Neuroscience, Inc.ANRO	Pharmaceutical Preparations	$993M	$23.19	4.9%	—	—	—	—	—	—	—	−$51.8M	—	—	−41.8%	−$160M	—	—	17.3%	2	$0.0M	$3.6M
Rigel Pharmaceuticals IncRIGL	Pharmaceutical Preparations	$989M	$50.55	1.3%	$294M	64.1%	42.6%	3.0x	22.1%	93.3%	124.7%	—	—	43.4%	185.9%	−$102M	−0.8x	—	6.5%	6	$0.0M	$0.0M
MoonLake ImmunotherapeuticsMLTX	Pharmaceutical Preparations	$882M	$11.93	1.0%	—	—	—	—	—	—	—	−$196M	—	—	−60.5%	−$320M	—	—	2.5%	1	$0.0M	$0.0M
Kura Oncology, Inc.KURA	Pharmaceutical Preparations	$880M	$9.90	2.9%	$67.5M	25.2%	−449.9%	—	—	—	−412.9%	−$70.7M	−104.8%	—	−94.8%	−$658M	—	—	1.8%	2	$2.4M	$1.7M
Arbutus Biopharma CorpABUS	Pharmaceutical Preparations	$847M	$4.29	2.1%	$14.1M	128.2%	−271.0%	5.4x	15.3%	—	−237.9%	−$39.6M	−281.5%	—	−38.5%	−$91.5M	—	—	3.2%	3	$0.0M	$0.0M
Ardelyx, Inc.ARDX	Pharmaceutical Preparations	$744M	$3.00	0.0%	$407M	22.1%	−10.1%	—	121.9%	90.3%	−15.1%	−$44.0M	−10.8%	−30.8%	−36.2%	−$61.9M	—	—	2.5%	3	$0.0M	$0.5M
Inventiva S.A.IVA	Pharmaceutical Preparations	$688M	$3.69	0.7%	$5.1M	−49.2%	−3,145.5%	—	64.2%	—	−7,899.5%	—	—	—	—	−$46.4M	—	—	212.5%	3	$0.0M	$0.0M
Lexicon Pharmaceuticals, Inc.LXRX	Pharmaceutical Preparations	$648M	$1.48	2.1%	$49.8M	60.2%	−98.2%	—	15.7%	99.4%	−101.1%	−$67.9M	−136.2%	−59.2%	−39.7%	−$42.2M	—	—	13.4%	4	$0.0M	$0.0M
Zevra Therapeutics, Inc.ZVRA	Pharmaceutical Preparations	$617M	$10.06	5.5%	$106M	350.9%	−59.1%	10.7x	51.6%	—	78.2%	−$2.4M	−2.3%	−236.3%	85.7%	−$129M	—	—	23.8%	5	$0.0M	$0.8M
Puma Biotechnology, Inc.PBYI	Pharmaceutical Preparations	$574M	$10.92	0.6%	$228M	−0.9%	16.3%	21.0x	0.3%	74.5%	13.6%	$41.7M	18.3%	58.4%	28.0%	−$74.9M	−1.6x	—	3.2%	7	$0.0M	$0.6M
Evotec SEEVO	Pharmaceutical Preparations	$558M	$1.57	3.3%	$889M	3.1%	−7.1%	—	9.3%	14.5%	−13.1%	−$92.2M	−10.4%	−6.3%	−12.0%	−$167M	−3.4x	$1.7M	0.2%	5	$0.0M	$0.0M
Aquestive Therapeutics, Inc.AQST	Pharmaceutical Preparations	$509M	$4.07	2.5%	$44.5M	−22.6%	−159.5%	—	−0.6%	58.3%	−188.1%	−$53.0M	−119.0%	—	—	−$66.2M	—	—	23.3%	2	$0.0M	$0.4M
Arvinas, Inc.ARVN	Pharmaceutical Preparations	$489M	$7.45	1.9%	$263M	−0.3%	−45.1%	31.0x	58.9%	—	−30.8%	−$276M	−105.0%	—	−16.2%	−$685M	—	$91.9M	−1.4%	4	$0.0M	$0.0M
Kamada LtdKMDA	Pharmaceutical Preparations	$470M	$8.05	1.4%	$180M	12.1%	14.5%	23.0x	6.3%	42.3%	11.2%	—	—	11.1%	7.6%	−$65.5M	−2.4x	$11.5M	0.9%	7	$0.0M	$1.7M
Opus Genetics, Inc.IRD	Pharmaceutical Preparations	$385M	$3.46	4.2%	$14.2M	29.1%	−271.9%	—	—	—	−349.3%	—	—	—	−449.4%	−$44.0M	—	—	132.9%	3	$0.0M	$2.9M
Altimmune, Inc.ALT	Pharmaceutical Preparations	$378M	$2.04	0.5%	$0.0M	105.0%	−230,461.0%	—	−65.3%	—	−214,861.0%	−$67.5M	−164,746.3%	—	−50.6%	−$239M	—	—	24.1%	4	$0.0M	$0.0M
ARS Pharmaceuticals, Inc.SPRY	Pharmaceutical Preparations	$370M	$3.73	4.8%	$84.3M	−5.5%	−212.9%	—	—	—	−203.3%	−$171M	−203.1%	—	−92.3%	−$149M	—	—	−3.7%	3	$0.0M	$0.0M
Abeona Therapeutics Inc.ABEO	Pharmaceutical Preparations	$254M	$4.45	3.2%	$5.8M	—	−1,536.9%	—	−10.3%	73.7%	1,223.1%	−$84.3M	−1,448.5%	—	70.0%	−$171M	—	—	61.1%	4	$0.0M	$0.3M
ADC Therapeutics SAADCT	Pharmaceutical Preparations	$246M	$1.59	5.3%	$81.4M	14.9%	−149.3%	—	—	92.9%	−175.3%	−$141M	−173.8%	—	—	−$258M	—	—	30.8%	5	$0.0M	$0.0M
BioAge Labs, Inc.BIOA	Pharmaceutical Preparations	$245M	$5.47	9.6%	$9.0M	—	−1,031.5%	—	—	—	−896.1%	−$82.3M	−915.5%	—	−27.1%	−$278M	—	—	235.0%	3	$0.0M	$0.0M
Cartesian Therapeutics, Inc.RNAC	Pharmaceutical Preparations	$193M	$6.46	2.9%	$2.8M	−92.8%	−5,127.1%	—	−30.0%	—	−4,658.6%	−$79.4M	−2,838.6%	—	—	−$125M	—	—	49.6%	1	$0.0M	$0.0M
Akebia Therapeutics, Inc.AKBA	Pharmaceutical Preparations	$178M	$0.66	2.6%	$236M	47.5%	9.9%	—	−4.3%	83.3%	−2.3%	$67.7M	28.7%	—	—	−$137M	−5.5x	—	21.9%	6	$0.0M	$0.0M
Adagene Inc.ADAG	Pharmaceutical Preparations	$152M	$2.58	3.6%	$7.7M	7,333.0%	−279.5%	—	61.4%	—	−229.6%	−$15.7M	−204.3%	—	−41.0%	−$67.7M	—	—	4.8%	5	$0.2M	$0.0M
Alx Oncology Holdings IncALXO	Pharmaceutical Preparations	$149M	$1.10	2.7%	—	—	—	—	—	—	—	−$84.4M	—	—	−145.7%	−$33.1M	—	—	2.8%	1	$0.0M	$0.0M
Perspective Therapeutics, Inc.CATX	Pharmaceutical Preparations	$144M	$1.19	1.7%	$0.9M	−39.2%	−12,846.6%	—	−38.5%	—	−11,665.3%	−$95.2M	−10,773.0%	−140.4%	−41.4%	−$143M	—	—	14.6%	1	$0.0M	$1.3M
ProQR Therapeutics N.V.PRQR	Pharmaceutical Preparations	$141M	$1.34	8.1%	$17.9M	−12.3%	−273.1%	—	—	—	−265.2%	−$60.7M	−338.3%	—	−63.4%	−$103M	—	—	22.4%	1	$0.4M	$0.0M
Medicus Pharma Ltd.MDCX	Pharmaceutical Preparations	$135M	$2.45	2.4%	−$0.2M	−877.2%	17,405.9%	—	—	—	23,952.1%	—	—	—	−3,083.1%	−$3.5M	—	—	79.7%	1	$0.0M	$0.0M

What do these columns mean?

Market cap: Last close times the latest diluted share count, so it is approximate.
Price: Closing share price on the last trading day.
Day change: Change in the closing price against the previous trading day's close.
Revenue: Total sales reported in the income statement.
Revenue growth: Change in revenue against the year (or quarter) a year earlier.
Operating margin: Operating income as a share of revenue.
P/E: Last close divided by diluted earnings per share over the last four quarters.
5-yr growth: Revenue growth a year, compounded over the last five years.
Gross margin: Gross profit as a share of revenue.
Net margin: Net income as a share of revenue.
Free cash flow: Cash from operations minus capital spending.
FCF margin: Free cash flow as a share of revenue.
Return on capital: After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Return on equity: Net income as a share of average shareholders' equity.
Net debt: Debt and finance leases minus cash and short-term investments. Negative means net cash.
Net debt / EBITDA: Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
Dividends + buybacks: Cash returned to shareholders through dividends and share repurchases.
Share count change: Change in the diluted share count. Negative means buybacks shrank it.
F-score: Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
Industry: The industry the company reports under, from its SEC filing code. Click it to see its peers.
Colours and dashes: Green is up or growing, red is down or shrinking. — means no data, or a P/E that is not meaningful (losses, or above 200).
Units: M = millions, B = billions, T = trillions, in USD. Fundamentals use the latest fiscal year. Use “Edit columns” to show more figures, hide some or change their order.